Great Debates

One Week Away! Highlighted Session at Great Debates in Solid Tumors Join us in NYC March 22–23 as Dr. kathleen moore explores the future of Antibody Drug Conjugates in gynecologic cancer. Gain critical insights into optimal patient selection, promising targets, and implications for clinical practice. This is one session you don’t want to miss. Use code MARCHLAST to save and secure your spot now: https://lnkd.in/e4s5E8zV #GDST25 #MedicalEducation #Cancer #WomensCancer

Engage with leading experts in hematology-oncology at?Great Debates in Hematologic Malignancies, where cutting-edge advancements and controversial topics in blood cancer care take center stage. Big Questions. Bold Debates. Better Outcomes. ?? hmpglobalevents.com/gdhem

Results from the phase 3 EXCLAIM-2 trial found that first-line #mobocertinib failed to improve efficacy compared to platinum-based #chemotherapy among patients with EGFR-mutated locally advanced or metastatic NSCLC. Learn more: https://hubs.ly/Q03bkwcw0

There’s still time to join us at?Great Debates in Solid Tumors, March 22–23 in New York City! Why Attend? Freely choose from sessions across Women’s, Lung, and Gastrointestinal cancer tracks to create an agenda that fits your clinical needs. Hear directly from leading oncology experts, including Drs. Namrata (Neena) Vijayvergia, MD, FACP, Heather Moore, and Deborah Doroshow. Don’t miss these essential sessions to enhance your practice and patient care. Register now with code?MARCHLAST?to save: gdsolidtumors.com #GDST25 #MedicalEducation #Cancer #GreatDebates

Nagla Abdel Karim, MD, PhD, Inova Schar Cancer Institute, discusses phase 2 study results which demonstrated that the addition of #talazoparib to maintenance #atezolizumab improved survival outcomes for patients with SLFN11-positive extensive-stage #SCLC. Learn more: https://lnkd.in/e9BpcJbU

Updated results from the phase 3 PRECIOUS study demonstrated that retreatment with #pertuzumab improved survival among patients with HER2-positive advanced breast cancer. Learn more: https://lnkd.in/erZcDDd4

The Evolving PI3K Landscape in HR+ Metastatic Breast Cancer Join Dr. Seth Wander (Massachusetts General Hospital) and Dr. Kelly McCann (UCLA) in a thought-provoking discussion on how PI3K pathway alterations impact HR+ metastatic breast cancer treatment. They’re joined by Drs. Megan Kruse and Janice Lu to explore strategies for genomic testing, novel targeted therapies, and practical clinical considerations. ?? https://bit.ly/3QOPlrD If you’re interested in learning more from Dr. Wander and Dr. McCann, they’ll both be speaking at Great Debates in Solid Tumors—a can’t miss event for deeper insights on emerging oncology trends. https://lnkd.in/esd-e_94 #BreastCancer #PI3K #MedicalEducation #GDST25 #Oncology

This Colorectal Cancer Awareness Month is a powerful reminder that screening and prevention can save lives. By encouraging timely colonoscopies, proactive discussions with patients, and the latest evidence-based guidelines, we can make a tangible impact on colorectal cancer outcomes. At Great Debates in Solid Tumors, we strive to support oncology professionals with practical, real-world education that helps move the needle on patient care. #ColorectalCancer #Oncology #GDST #CancerAwareness #ScreeningSavesLives

We’re excited to announce that leading experts from Memorial Sloan Kettering Cancer Center will be sharing their insights at?Great Debates in Solid Tumors! Join us as?Drs. Yelena Janjigian (Co-chair), Jamie Chaft, Samuel Cytryn, James J Harding, Ying Liu, Helena Yu, Nour Abuhadra,?and?Gregory Riely?contribute their expertise to dynamic discussions on the latest advancements in solid tumor care. Don’t miss this opportunity to learn from some of the brightest minds in oncology. ?? Register today: gdsolidtumors.com #GDST25 #MedicalEducation #MSKCC #Cancer

The Promise & Complexity of Bispecific Antibodies Chris Van Denburg explores why bispecific antibodies hold great potential for cancer treatment—and why adoption has been slower than expected. From managing immune-related toxicities to navigating reimbursement hurdles, learn about the factors influencing their uptake in the community setting. Dive Deeper: https://lnkd.in/gTyK77Cv Are you a community oncologist looking to stay informed on the latest in cancer treatment? Consider attending Great Debates in Solid Tumors. ???gdsolidtumors.com #BispecificAntibodies #Oncology #Cancer #MedicalEducation